All In Biotech

Drug Trial Radar · NCT07712588

Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)

A Phase 2/3, Randomized, Double-Blind, Multi-center Study of Birelentinib Combined With R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 880 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

880

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Jan 2031

Study completion Feb 2032

Sponsor

Lead sponsor
Dizal PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of birelentinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP.

Conditions

  • Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions

  • BirelentinibDrug

    Specified dose on specified days

  • RituximabDrug

    Specified dose on specified days

  • CyclophosphamidDrug

    Specified dose on specified days

  • DoxorubicinDrug

    Specified dose on specified days

  • VincristineDrug

    Specified dose on specified days

  • PrednisoneDrug

    Specified dose on specified days

  • PlaceboDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Incidence and severity of adverse eventsTime frame: Up to 2 years
  2. Part B: Progression-free survival (PFS)Time frame: Up to 5 years

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Cancer Hospital of Shandong Frist Medical University

    Jinan, Shangdong, China

  • Shanghai Jiao Tong University School of Medicine, Ruijin Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.